Apomorphine still leads, but ropinirole expands emetic options

CURRENT FULL VERSION: The debate over apomorphine versus ropinirole as the go-to emetic in dogs is moving from theory to evidence. VetGirl recently spotlighted the comparison in a continuing education podcast, framing the practical question many ER teams are asking: whether topical ropinirole can match IV apomorphine for dogs that have just ingested a toxin or foreign material. The broader literature now gives clinicians a clearer picture: ropinirole is a credible canine emetic, but apomorphine may still be the stronger choice when speed and first-dose reliability matter most in emergency presentations. (pubmed.ncbi.nlm.nih.gov)

Ropinirole changed the landscape when the FDA approved Clevor in June 2020 for induction of vomiting in dogs. That approval gave veterinarians an ophthalmic dopamine agonist with a labeled indication in dogs, and, as VetGirl noted, the only FDA-approved veterinary emetic for this use, rather than relying on apomorphine alone through injectable, conjunctival, or other routes. In the FDA-reviewed field study, 95% of dogs treated with ropinirole vomited within 30 minutes, and 86% did so after the first dose. The product is prescription-only and intended for administration by veterinary personnel, reflecting the need to assess contraindications and monitor adverse reactions. (fda.gov)

Since approval, comparative data have become more detailed. A 2023 JAVMA study of 279 client-owned dogs with suspected toxin or foreign material ingestion found that 91.4% vomited after ropinirole administration, with a mean time to emesis of 11 minutes and adverse effects reported in 17% of dogs; the authors concluded ropinirole was safe and effective, but slightly less effective than apomorphine for inducing vomiting overall. A newer 2025 randomized crossover trial in 24 healthy dogs found near-equivalent success rates, with 95.8% for IV apomorphine and 100% for ophthalmic ropinirole, and concluded the two had similar efficacy and adverse-effect rates under controlled conditions. (pubmed.ncbi.nlm.nih.gov)

But the emergency-room picture may be more complicated. In the 2025 Journal of Veterinary Emergency and Critical Care trial highlighted by VetGirl, investigators enrolled 132 client-owned dogs at two specialty referral hospitals from October 2021 through March 2023 after suspected or confirmed ingestion of a toxin or foreign body. Dogs were randomized to ropinirole eye drops (63 dogs) or IV apomorphine (69 dogs), with a second identical dose allowed if vomiting had not occurred within 20 minutes and monitoring continued for 40 minutes. The case mix included toxic foods, plants, medications, rodenticides and other poisons, as well as foreign material such as toys, cords, cloth, and personal items. Dogs were excluded if they were younger than 4.5 months, weighed less than 1.8 kg, had ocular disease, central nervous system or hepatic disease, had ingested a substance for which emesis was contraindicated such as caustics or volatile agents, or had already received antiemetics. In that real-world ER setting, ropinirole had a lower first-dose success rate, a longer median time to the first emetic event, more minor adverse events, and more protracted vomiting requiring rescue therapy than IV apomorphine. The authors concluded that apomorphine was the clinically superior emetic agent for dogs in emergency presentations requiring rapid decontamination. That finding is especially relevant for ER teams making time-sensitive decisions after recent ingestion. (pubmed.ncbi.nlm.nih.gov)

Expert and industry-facing educational sources broadly reflect that same split view. Today’s Veterinary Practice describes ropinirole as the first FDA-approved emetic for dogs and outlines its practical dosing advantages as an ophthalmic product, while also noting that apomorphine remains a standard option in dogs. A 2025 toxicology review from Laura Stern, DVM, DABVT, DABT, at ASPCA Animal Poison Control Center emphasizes that induction of emesis can reduce risk after toxin ingestion, but also warns that it is not benign and can lead to complications including protracted vomiting and aspiration pneumonia. In other words, the conversation is not simply which drug is “better,” but which drug best matches the patient, the ingestion, and the clinic’s capabilities. (todaysveterinarypractice.com)

Why it matters: For veterinary professionals, this is a workflow and case-management question as much as a pharmacology one. Ropinirole’s ophthalmic route may help in practices where IV access is less convenient, where staff want an FDA-approved canine product, or where avoiding injection is a practical advantage. Apomorphine, however, still appears to offer meaningful clinical benefits in urgent decontamination scenarios, particularly when every minute counts and first-dose success is important. The emerging evidence suggests that ropinirole is not replacing apomorphine outright, but expanding the toolkit. Just as important, the ER trial and toxicology guidance reinforce that not every ingestion case is an emesis case: timing, product type, aspiration risk, neurologic status, and other contraindications still need to be checked before either drug is used. (fda.gov)

There are also species and safety boundaries to keep in view. Ropinirole is approved for dogs, not cats, and current pharmacology references note that, like apomorphine, it is not expected to be effective in cats because of species differences in emetic receptor pathways. More broadly, toxicology guidance stresses that clinicians should first confirm timing, dose, formulation, contraindications, neurologic status, and aspiration risk before choosing any emetic strategy. That makes protocol development, staff training, and client communication just as important as the drug choice itself. (todaysveterinarypractice.com)

What to watch: The next step is likely more real-world comparison data in emergency and primary care settings, especially around first-dose success, adverse-event management, and which cases benefit most from ophthalmic versus injectable induction of emesis. If those findings continue to diverge by setting, clinics may increasingly build protocol-driven pathways that reserve apomorphine for the highest-urgency canine decontamination cases and use ropinirole more selectively. On the antiemetic side, Dechra has also announced FDA approval of Emeprev, an injectable maropitant product positioned as the first FDA-approved bioequivalent to the leading antiemetic in dogs and cats. The company says the formulation includes benzyl alcohol that reduces injection pain in dogs, does not require refrigeration, and is expected to reach major veterinary distributors in early 2026—details that could matter for clinics managing post-emesis nausea or vomiting more broadly. (pubmed.ncbi.nlm.nih.gov)